文献速递淋巴瘤造血干细胞移植与细胞治疗

淋巴瘤自体干细胞移植背景下克隆性造血的临床意义

Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma.
PubMed 文献 · Am J Hematol · 2022-09-26

该研究对420例淋巴瘤患者采用超深度纠错测序检测干细胞产品中的克隆性造血(CH),181例(43.1%)检出CH,T细胞淋巴瘤最常见(72.2%);CH与中性粒细胞和血小板恢复时间延长相关,且CH患者自首次复发和自ASCT起的5年总生存均较差, adverse OS主要与PPM1D突变相关(HR 1.74,95%CI 1.13-2.67,p=.011),CH与治疗相关髓系肿瘤发生率低且无显著差异。

要点

  • 420例淋巴瘤患者中43.1%在干细胞产品中检出CH,T细胞淋巴瘤最常见(72.2%)。
  • CH患者中性粒细胞和血小板恢复时间更长,5年OS自首次复发39.4% vs 45.8%(p=.043),自ASCT 51.8% vs 59.3%(p=.018)。
  • adverse OS主要与PPM1D突变相关(HR 1.74,95%CI 1.13-2.67,p=.011)。

核心结论

  • CH与ASCT后非淋巴瘤相关死亡风险增加相关,提示伴CH的淋巴瘤幸存者可能需要加强监测策略以预防和治疗晚期并发症。

研究设计与样本

  • 研究纳入420例淋巴瘤患者,采用超深度、高灵敏度纠错测序检测干细胞产品样本中的CH。

主要发现

  • 181例(43.1%)患者干细胞产品中检出CH,T细胞淋巴瘤中最常见(72.2%)。
  • CH与中性粒细胞和血小板恢复时间延长相关。
  • CH患者自首次复发起的5年OS为39.4% vs 45.8%(p=.043),自ASCT起的5年OS为51.8% vs 59.3%(p=.018)。
  • CH的不良预后影响并非由治疗相关髓系肿瘤导致,其10年累积发生率在伴和不伴CH者分别为3.3% vs 3.0%(p=.445)。
  • adverse OS主要与PPM1D突变相关(HR 1.74,95%CI 1.13-2.67,p=.011)。

临床怎么用

  • 作者认为,伴CH的淋巴瘤幸存者可能需要加强监测策略以预防和治疗晚期并发症。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous stem cell transplantation (ASCT) remains a key therapeutic strategy for treating patients with relapsed or refractory non-Hodgkin and Hodgkin lymphoma. Clonal hematopoiesis (CH) has been proposed as a major contributor not only to the development of therapy-related myeloid neoplasms but also to inferior overall survival (OS) in patients who had undergone ASCT. Herein, we aimed to investigate the prognostic implications of CH after ASCT in a cohort of 420 lymphoma patients using ultra-deep, highly sensitive error-correction sequencing. CH was identified in the stem cell product samples of 181 patients (43.1%) and was most common in those with T-cell lymphoma (72.2%). The presence of CH was associated with a longer time to neutrophil and platelet recovery. Moreover, patients with evidence of CH had inferior 5-year OS from the time of first relapse (39.4% vs. 45.8%, p = .043) and from the time of ASCT (51.8% vs. 59.3%, p = .018). The adverse prognostic impact of CH was not due to therapy-related myeloid neoplasms, the incidence of which was low in our cohort (10-year cumulative incidence of 3.3% vs. 3.0% in those with and without CH, p = .445). In terms of specific-gene mutations, adverse OS was mostly associated with PPM1D mutations (hazard ratio (HR) 1.74, 95% confidence interval (CI) 1.13-2.67, p = .011). In summary, we found that CH is associated with an increased risk of non-lymphoma-related death after ASCT, which suggests that lymphoma survivors with CH may need intensified surveillance strategies to prevent and treat late complications.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Lackraj T, Ben Barouch S, Medeiros JJF, et al. Clinical significance of clonal hematopoiesis in the setting of autologous stem cell transplantation for lymphoma. Am J Hematol. 2022. PMID: 36087071. doi:10.1002/ajh.26726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。